» Articles » PMID: 7982059

Neuroanatomical Distribution of Receptors for a Novel Voltage-sensitive Calcium-channel Antagonist, SNX-230 (omega-conopeptide MVIIC)

Overview
Journal Brain Res
Specialty Neurology
Date 1994 Aug 8
PMID 7982059
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Neuronal voltage-sensitive calcium channels (VSCCs) are a diverse family of proteins that regulate entry of Ca2+ into neurons. Selective antagonists of VSCCs have proven to be powerful pharmacological tools for identifying and characterizing these channels. A new VSCC antagonist, SNX-230 (also known as omega-conopeptide MVIIC), binds with high affinity to receptors in rat brain and blocks one or more high-threshold VSCCs that are neither L- nor N-type. We have defined the neuroanatomical distribution of the high-affinity non-L, non-N VSCC receptors for SNX-230 using [125I]SNX-230 bound to rat brain sections and compared it with that of [125I]SNX-111, a reversible blocker of N-type VSCCs. Highest densities of binding for both ligands were seen in areas rich in synaptic connections, such as the oriens, radiatum and molecular layers of the hippocampus. In general, the density of [125I]SNX-230-binding was higher in cerebellum compared with that in forebrain. In contrast, this general distribution of density was reversed for [125I]SNX-111. In the glomeruli of the olfactory bulb, binding of [125I]SNX-230 was undetectable compared with the high density of [125I]SNX-111-binding. Differential localization of the two ligands was also seen in cervical spinal cord. The clearly different localization of [125I]SNX-230 compared with that of [125I]SNX-111 in the olfactory bulb and spinal cord suggested that the binding sites for [125I]SNX-230 in other brain regions, while co-localized macroscopically, are also distinct from those for [125I]SNX-111. This was confirmed when addition of saturating concentrations of SNX-111 did not affect the distribution pattern of [125I]SNX-230-binding.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Omega-conotoxin MVIIA reduces neuropathic pain after spinal cord injury by inhibiting N-type voltage-dependent calcium channels on spinal dorsal horn.

Ohashi N, Uta D, Ohashi M, Hoshino R, Baba H Front Neurosci. 2024; 18:1366829.

PMID: 38469570 PMC: 10925679. DOI: 10.3389/fnins.2024.1366829.


Subcutaneous ω-Conotoxins Alleviate Mechanical Pain in Rodent Models of Acute Peripheral Neuropathy.

Hasan M, Starobova H, Mueller A, Vetter I, Lewis R Mar Drugs. 2021; 19(2).

PMID: 33670311 PMC: 7917901. DOI: 10.3390/md19020106.


Marine Toxins and Nociception: Potential Therapeutic Use in the Treatment of Visceral Pain Associated with Gastrointestinal Disorders.

Baj A, Bistoletti M, Bosi A, Moro E, Giaroni C, Crema F Toxins (Basel). 2019; 11(8).

PMID: 31370176 PMC: 6723473. DOI: 10.3390/toxins11080449.


Psychotropic Drugs for the Management of Chronic Pain and Itch.

Belinskaia D, Belinskaia M, Barygin O, Vanchakova N, Shestakova N Pharmaceuticals (Basel). 2019; 12(2).

PMID: 31238561 PMC: 6631469. DOI: 10.3390/ph12020099.


Near-resolution of persistent idiopathic facial pain with low-dose lumbar intrathecal ziconotide: a case report.

Staub B, Casini G, Monaco 3rd E, Sekula Jr R, Emerick T J Pain Res. 2019; 12:945-949.

PMID: 30881103 PMC: 6413753. DOI: 10.2147/JPR.S193746.